CLAIMS

1. An aqueous composition having a pH of 5.0-7.0 and comprising
   (i) an anti-BAFFR antibody wherein the antibody has a concentration of 18 - 165 mg/mL, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
   (ii) a stabilizer,
   (iii) a buffering agent,
   (iv) a surfactant, and, optionally,
   (v) an amino acid.

2. The aqueous composition of claim 1 having a pH of 5.5-6.5 and comprising
   (i) an anti-BAFFR antibody wherein the antibody has a concentration of 18-165 mg/mL, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
   (ii) sucrose, trehalose or mannitol as a stabilizer,
   (iii) histidine, citrate or succinate as a buffering agent,
   (iv) polysorbate 20, poloxamer 188 or hydroxyproyl-b-cyclodextrin as a surfactant, and, optionally,
   (v) arginine as an amino acid.

3. The aqueous composition of claim 1 or claim 2 comprising the anti-BAFFR antibody in a concentration of between 20 mg/mL and 150 mg/mL.

4. The aqueous composition of any one of the preceding claims comprising sucrose, mannitol or trehalose, in a concentration of between 80 mM and 300 mM.

5. The aqueous composition of any one of the preceding claims comprising polysorbate 20 or poloxamer 188, in a concentration of between 0.01% and 0.1%.

6. The aqueous composition of any one of the preceding claims comprising histidine, citrate or succinate, in a concentration of between 5 mM and 50 mM.

7. The aqueous composition of any one of the preceding claims comprising arginine, particularly arginine-HCl, in a concentration of between 2 mM and 80 mM.

8. The aqueous composition of any one of the preceding claims comprising sucrose or trehalose in a concentration of between 110 mM and 250 mM.

9. The aqueous composition of any one of the preceding claims comprising sucrose or trehalose in a concentration of between 120 mM and 220 mM.

10. The aqueous composition of any one of the preceding claims comprising polysorbate 20 in a concentration of between 0.02% and- 0.06%.

11. The aqueous composition of any one of the preceding claims comprising histidine in a concentration of between 15 mM and 25 mM.

12. The aqueous composition of any one of the preceding claims comprising arginine, particularly arginine-HCl, in a concentration of between 18 mM and 22 mM.

13. The aqueous composition of claim 1 having a pH of 5.5-6.5 and comprising
    (i) an anti-BAFFR antibody wherein the antibody has a concentration of 18 mg/mL - 165 mg/mL, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
    (ii) 80 mM - 300 mM sucrose, trehalose or mannitol as a stabilizer,
    (iii) 5 mM -50 mM histidine, citrate or succinate as a buffering agent,
    (iv) 0.01% - 0.1% polysorbate 20 or poloxamer 188, or 1 mM – 3 mM hydroxyproyl-b-cyclodextrin as a surfactant, and, optionally,
    (v) 2 mM - 80 mM arginine, particularly arginine-HCl.

14. The aqueous composition of claim 1 having a pH of 5.5-6.5 and comprising
    (i) an anti-BAFFR antibody wherein the antibody has a concentration of 20 mg/mL - 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
    (ii) 110 mM - 250 mM sucrose or trehalose as a stabilizer,
    (iii) 15 mM - 25 mM histidine, citrate or succinate as a buffering agent,
    (iv) up to 0.02% - 0.06% polysorbate 20 or poloxamer 188 or 2 mM – 3 mM hydroxyproyl-b-cyclodextrin as a surfactant, and, optionally,
    (v) 2 mM - 80 mM arginine, particularly arginine-HCl.

15. The aqueous composition of claim 1 having a pH of 5.5-6.5 and comprising

(i) an anti-BAFFR antibody wherein the antibody has a concentration of 20 mg/mL - 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,

(ii) 120 mM - 220 mM sucrose or trehalose as a stabilizer,

(iii) 18 mM - 22 mM histidine, citrate or succinate as a buffering agent,

(iv) up to 0.02% - 0.06% polysorbate 20 or poloxamer 188 or 2,5 mM hydroxyproyl-b-cyclodextrin as a surfactant, and optionally

(v) 2 mM - 80 mM arginine, particularly arginine-HCl.

16. The aqueous composition of claim 1 having a pH of 6.0 and comprising

(i) an anti-BAFFR antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,

(ii) 220 mM sucrose as a stabilizer,

(iii) 20 mM histidine as a buffering agent,

(iv) 0.04% polysorbate 20 as a surfactant.

17. The aqueous composition of claim 1 having a pH of 6.0 and comprising

(i) an anti-BAFFR antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,

(ii) 220 mM trehalose as a stabilizer,

(iii) 20 mM histidine as a buffering agent,

(iv) 0.04% polysorbate 20 as a surfactant.

18. The aqueous composition of claim 1 having a pH of 6.0 and comprising

(i) an anti-BAFFR antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,

(ii) 120 mM sucrose as a stabilizer,

(iii) 20 mM histidine as a buffering agent,

(iv) 0.04% polysorbate 20 as a surfactant, and

(v) 50 mM arginine, particularly arginine-HCl.

19. The aqueous composition of claim 1 having a pH of 6.0 and comprising
    (i) an anti-BAFFR antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
    (ii) 120 mM trehalose as a stabilizer,
    (iii) 20 mM histidine as a buffering agent,
    (iv) 0.04% polysorbate 20 as a surfactant, and
    (v) 50 mM arginine, particularly arginine-HCl.

20. The aqueous composition of claim 1 having a pH of 6.0 and comprising
    (i) an anti-BAFFR antibody wherein the antibody has a concentration of 20 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
    (ii) 220 mM sucrose as a stabilizer,
    (iii) 20 mM histidine as a buffering agent, and
    (iv) 0.04% polysorbate 20 as a surfactant.

21. The aqueous composition of claim 1 having a pH of 6.0 and comprising
    (i) an anti-BAFFR antibody wherein the antibody has a concentration of 20 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,
    (ii) 220 mM trehalose as a stabilizer,
    (iii) 20 mM histidine as a buffering agent, and
    (iv) 0.04% polysorbate 20 as a surfactant.

22. The aqueous composition of any one of the preceding claims, wherein the anti-BAFFR antibody comprises a V_H domain with amino acid SEQ ID NO: 1 and a V_L domain with amino acid SEQ ID NO: 2.

23. The aqueous composition of any one of the preceding claims, wherein the anti-BAFFR antibody comprises a heavy chain region of SEQ ID NO: 9 and a light chain region of SEQ ID NO: 10.

24. The aqueous composition of any one of the preceding claims, wherein the anti-BAFFR antibody is non-fucosylated.

25. A delivery device comprising the aqueous composition according to any one of claims 1-24.

26. A pre-filled syringe comprising the aqueous composition according to any one of claims 1-24.

27. A method for delivering an anti-BAFFR antibody to a mammal, comprising the step of administering to said mammal an aqueous composition according to any one of claims 1-24.

28. The aqueous composition according to any one of claims 1-24, or the delivery device of claim 25, or the pre-filled syringe of claim 26, for use in the treatment of a disease or disorder that is mediated by BAFF receptor or that can be treated by killing or depleting B cells.

29. The aqueous composition according to any one of claims 1-24, or the delivery device of claim 25, or the pre-filled syringe of claim 26, for use in the treatment of an autoimmune disease.

30. The aqueous composition according to any one of claims 1-24, or the delivery device of claim 25, or the pre-filled syringe of claim 26, for use in the treatment of a B cell neoplasm, such as lymphoma, leukemia or myeloma.

31. The aqueous composition according to any one of claims 1-24, or the delivery device of claim 25, or the pre-filled syringe of claim 26, for use in the treatment of rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, or Pemphigus vulgaris.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An aqueous composition having a pH of 6.0 and comprising a hypofucosylated or non-fucosylated anti-BAFFR antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8, and

(a) (ii) 220 mM sucrose as a stabilizer,
(iii) 20 mM histidine as a buffering agent,
(iv) 0.04% polysorbate 20 as a surfactant; or

(b) (ii) 220 mM trehalose as a stabilizer,
(iii) 20 mM histidine as a buffering agent,
(iv) 0.04% polysorbate 20 as a surfactant; or

(c) (ii) 120 mM sucrose as a stabilizer,
(iii) 20 mM histidine as a buffering agent,
(iv) 0.04% polysorbate 20 as a surfactant, and
(v) 50 mM arginine, particularly arginine-HCl.

2. The aqueous composition of claim 1, wherein the hypofucosylated or non-fucosylated anti-BAFFR antibody comprises a V_H domain with amino acid SEQ ID NO: 1 and a V_L domain with amino acid SEQ ID NO: 2.

3. The aqueous composition of claim 1 or 2, wherein the hypofucosylated or non-fucosylated anti-BAFFR antibody comprises a heavy chain region of SEQ ID NO: 9 and a light chain region of SEQ ID NO: 10.

4. A delivery device comprising the aqueous composition according to any one of claims 1-3.

5. A pre-filled syringe comprising the aqueous composition according to any one of claims 1-3.

6. The aqueous composition according to any one of claims 1-3, or the delivery device of claim 4, or the pre-filled syringe of claim 5, for use in the treatment of a disease or disorder that is mediated by BAFF receptor or that can be treated by killing or depleting B cells.

7. The aqueous composition according to any one of claims 1-3, or the delivery device of claim 4, or the pre-filled syringe of claim 5, for use in the treatment of an autoimmune disease.

8. The aqueous composition according to any one of claims 1-3, or the delivery device of claim 4, or the pre-filled syringe of claim 5 , for use in the treatment of a B cell neoplasm, such as lymphoma, leukemia or myeloma.

9. The aqueous composition according to any one of claims 1-3, or the delivery device of claim 4, or the pre-filled syringe of claim 5, for use in the treatment of rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, multiple sclerosis or Pemphigus vulgaris.

10. Use of the aqueous composition according to any one of claims 1-3 in the manufacture of a medicament for treating or preventing a B cell neoplasm.

11. Use of the aqueous composition according to any one of claims 1-3 in the manufacture of a medicament for treating or preventing rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, multiple sclerosis or Pemphigus vulgaris.